Order

Notice - MITHAQ CANADA INC. and AIMIA INC., File No. 2023-28

Retrieved on: 
Monday, November 13, 2023
Order, Tribunal, Practice of law

TORONTO, Nov. 13, 2023 /CNW/ - The Tribunal issued an Order in the above-named matter.

Key Points: 

TORONTO, Nov. 13, 2023 /CNW/ - The Tribunal issued an Order in the above-named matter.
A copy of the Order dated November 13, 2023 and the Amended Application dated November 8, 2023 is available at capitalmarketstribunal.ca

TROY RICHARD JAMES HOGG, CRYPTOBONTIX INC., ARBITRADE EXCHANGE INC., ARBITRADE LTD., T.J.L. PROPERTY MANAGEMENT INC. and GABLES HOLDINGS INC., File No. 2022-20

Retrieved on: 
Friday, November 10, 2023
Order, Tribunal, Property management, Publishing

TORONTO, Nov. 10, 2023 /CNW/ - The Tribunal issued an Order in the above-named matter.

Key Points: 

TORONTO, Nov. 10, 2023 /CNW/ - The Tribunal issued an Order in the above-named matter.
A copy of the Order dated November 10, 2023 is available at capitalmarketstribunal.ca

EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million

Retrieved on: 
Thursday, December 14, 2023
XETRA, Financial services, Ruxolitinib, Relevance (Person of Interest), Frankfurt Stock Exchange, Regulation, Person, FSE, Wells Fargo, AMERICA, Qualification, Gross metropolitan product, Prospectus, Investment, EUR, Failure, MorphoSys, UBS, SEC Rule 144A, European Parliament, European Economic Area, Finance, BET, Council, Truist, Jefferies, Acquisition, EEA, Security (finance), Pharmaceutical industry, Order

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.

Key Points: 
  • The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.
  • “MorphoSys’ oncology pipeline offers promising value-creating opportunities, with pelabresib, our investigational BET inhibitor, at the forefront,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
  • “With pelabresib, we have the potential to shift the treatment paradigm in myelofibrosis, a field in dire need of innovation.
  • The placement price represents a discount of 2.8% compared to the 5-day volume-weighted average price (XETRA) of the Company’s shares.

The Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special Meeting

Retrieved on: 
Monday, November 6, 2023
Pharmaceutical, Professional Services, Health, Finance, Supreme court, TRO, Democracy, Human, Committee, Law of the United Kingdom, Exercise, Commonwealth, The, Supreme, Special, Hearing, Order, Security (finance), Management, Hy Averback

For the reasons detailed below, the Special Meeting will be postponed until further court rulings and CRNSV intends to steadfastly and vigorously pursue the urgent holding of the Special Meeting on behalf of all concerned Nymox shareholders within the Bahamian laws.

Key Points: 
  • For the reasons detailed below, the Special Meeting will be postponed until further court rulings and CRNSV intends to steadfastly and vigorously pursue the urgent holding of the Special Meeting on behalf of all concerned Nymox shareholders within the Bahamian laws.
  • Declaring premature and hollow “victories” is a trait of inexperienced and inward-looking leadership that has plagued Nymox for years.
  • Despite having validly called the Special Meeting pursuant to the Bahamian Supreme Court Order, Averback and his submissive Board have attempted to stymie shareholder voices from the very beginning.
  • The Bahamian Supreme Court Order clearly ordered the calling of a shareholder meeting by Nymox and if Nymox did not call the meeting, CRNSV was permitted to do so.

Ingersoll Rand Reports Record Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Machinery, Machine Tools, Metalworking & Metallurgy, Other Manufacturing, Manufacturing, Adjustment, Vacuum, NYSE, Public expenditure, IR, Ingersoll Rand Industrial Technologies, Share repurchase, Order, Acquisition, Ingersoll Rand, IT&S, Growth, EPS, M&A, Machining, Lifting, Pharmaceutical industry, Retail, Fine chemical, Q3

Ingersoll Rand Inc. (NYSE: IR) reported record third quarter revenues.

Key Points: 
  • Ingersoll Rand Inc. (NYSE: IR) reported record third quarter revenues.
  • Ingersoll Rand remains in a strong financial position with ample liquidity of $3.2 billion.
  • Consistent with our comprehensive capital allocation strategy led by M&A, in the third quarter of 2023, Ingersoll Rand deployed $308 million to M&A.
  • Ingersoll Rand closed on the acquisition of Howden Roots LLC (“Roots”), a leading provider of low-pressure compression and vacuum technologies.

The Committee to Restore Nymox Shareholder Value Reminds All Nymox Pharmaceutical Shareholders to Take Action and Demand Accountability at Upcoming November 8th Special Meeting

Retrieved on: 
Wednesday, November 1, 2023
Health, Pharmaceutical, Supreme court, BY, Attention, Committee, Law of the United Kingdom, Commonwealth, BOARD, The, Supreme, Partnership, Share repurchase, Record, Special, AND, Hy Averback, Arm's length principle, Patient, Order, Letter, Management

As shareholders, collectively, we have been given a critical opportunity to restore Nymox at the upcoming Special Meeting.

Key Points: 
  • As shareholders, collectively, we have been given a critical opportunity to restore Nymox at the upcoming Special Meeting.
  • With the Special Meeting under two weeks away, we encourage shareholders to make their voices heard and act now to install new leadership and a new Board.
  • Unlike the Company’s concerning disregard for compliance with the law, we understand the quorum requirements for holding a shareholder meeting.
  • We believe Nymox shareholders are intelligent and will realize that the Company has attempted to mislead shareholders for years.

Notice - ROYAL BANK OF CANADA, File No. 2023-32

Retrieved on: 
Friday, November 3, 2023
Approval, Settlement, Royal Bank, Oral reasons of the Supreme Court of Canada, Commission, Royal Bank of Canada, Order, Vexatious litigation, Indian Residential Schools Settlement Agreement, Tribunal, Pharmaceutical industry

TORONTO, Nov. 3, 2023 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission and Royal Bank of Canada.

Key Points: 
  • TORONTO, Nov. 3, 2023 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission and Royal Bank of Canada.
  • A copy of the Order dated November 3, 2023, Settlement Agreement dated October 25, 2023 and Oral Reasons for Approval of a Settlement dated November 3, 2023 are available at capitalmarketstribunal.ca